As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
-
COMMENTARY/Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
-
COMMENTARY/Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
-
COMMENTARY/Reform of Ethical Drug Distribution Practices
September 1, 2008
-
COMMENTARY/Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
-
COMMENTARY/Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
-
COMMENTARY 4 articles
July 28, 2008
-
COMMENTARY/Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
-
COMMENTARY/Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
-
COMMENTARY/Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
-
Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
-
COMMENTARY 4 articles
June 9, 2008
-
COMMENTARY/Shaking Pharmaceutical Administration System
May 19, 2008
-
COMMENTARY/Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
-
COMMENTARY/Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
-
COMMENTARY/Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
-
COMMENTARY/Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
-
COMMENTARY/Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
-
Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
-
COMMENTARY/Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…